Background: Several techniques are under investigation to improve the immunogenicity of HIV-1 DNA vaccine candidates. DNA vaccines are advantageous due to their ease of design, expression of multiple antigens, and safety. METHODS: The HVTN 098 trial assessed the PENNVAX®-GP DNA vaccine (encoding HIV env, gag, pol) administered with or without plasmid IL-12 at 0-, 1-, 3-, and 6-month timepoints via intradermal (ID) or intramuscular (IM) electroporation (EP) in healthy, adult participants. We report on safety, tolerability, and acceptability. RESULTS:HVTN 098 enrolled 94 participants: 85 receivedPENNVAX®-GP and nine received placebo. Visual analog scale (VAS) pain scores immediately after each vaccination were lower in the ID/EP than in the IM/EP group (medians 4.1-4.6 vs. 6-6.5, p < 0.01). IM/EP participants reported greater pain and/or tenderness at the injection site. Most ID/EP participants had skin lesions such as scabs/eschars, scars, and pigmentation changes, which resolved within 6 months in 51% of participants (24/55). Eighty-two percent of IM/EP and 92% of ID/EP participant survey responses showed acceptable levels of discomfort. CONCLUSIONS: ID/EP and IM/EP are distinct experiences; however, HIV-1 DNA vaccination by either route was safe, tolerable and acceptable by most study participants.
RCT Entities:
Background: Several techniques are under investigation to improve the immunogenicity of HIV-1 DNA vaccine candidates. DNA vaccines are advantageous due to their ease of design, expression of multiple antigens, and safety. METHODS: The HVTN 098 trial assessed the PENNVAX®-GP DNA vaccine (encoding HIV env, gag, pol) administered with or without plasmid IL-12 at 0-, 1-, 3-, and 6-month timepoints via intradermal (ID) or intramuscular (IM) electroporation (EP) in healthy, adult participants. We report on safety, tolerability, and acceptability. RESULTS: HVTN 098 enrolled 94 participants: 85 received PENNVAX®-GP and nine received placebo. Visual analog scale (VAS) pain scores immediately after each vaccination were lower in the ID/EP than in the IM/EP group (medians 4.1-4.6 vs. 6-6.5, p < 0.01). IM/EPparticipants reported greater pain and/or tenderness at the injection site. Most ID/EPparticipants had skin lesions such as scabs/eschars, scars, and pigmentation changes, which resolved within 6 months in 51% of participants (24/55). Eighty-two percent of IM/EP and 92% of ID/EPparticipant survey responses showed acceptable levels of discomfort. CONCLUSIONS: ID/EP and IM/EP are distinct experiences; however, HIV-1 DNA vaccination by either route was safe, tolerable and acceptable by most study participants.
Entities:
Keywords:
DNA vaccine; HIV vaccine; IL-12; electroporation; intradermal; intramuscular; safety
Authors: Katherine Schultheis; Trevor R F Smith; William B Kiosses; Kimberly A Kraynyak; Amelia Wong; Janet Oh; Kate E Broderick Journal: Hum Gene Ther Methods Date: 2018-08-10 Impact factor: 2.396
Authors: Pablo Tebas; Kimberly A Kraynyak; Ami Patel; Joel N Maslow; Matthew P Morrow; Albert J Sylvester; Dawson Knoblock; Elisabeth Gillespie; Dinah Amante; Trina Racine; Trevor McMullan; Moonsup Jeong; Christine C Roberts; Young K Park; Jean Boyer; Kate E Broderick; Gary P Kobinger; Mark Bagarazzi; David B Weiner; Niranjan Y Sardesai; Scott M White Journal: J Infect Dis Date: 2019-07-02 Impact factor: 5.226
Authors: David A Canton; Shawna Shirley; Jocelyn Wright; Richard Connolly; Christoph Burkart; Anandaroop Mukhopadhyay; Chris Twitty; Kristen E Qattan; Jean S Campbell; Mai H Le; Robert H Pierce; Sharron Gargosky; Adil Daud; Alain Algazi Journal: Immunotherapy Date: 2017-10-24 Impact factor: 4.196
Authors: Juliet Mpendo; Gaudensia Mutua; Julien Nyombayire; Rosine Ingabire; Annet Nanvubya; Omu Anzala; Etienne Karita; Peter Hayes; Jakub Kopycinski; Len Dally; Drew Hannaman; Michael A Egan; John H Eldridge; Kristen Syvertsen; Jennifer Lehrman; Beth Rasmussen; Jill Gilmour; Josephine H Cox; Patricia E Fast; Claudia Schmidt Journal: PLoS One Date: 2015-08-07 Impact factor: 3.240
Authors: Margherita Rosati; Mahesh Agarwal; Xintao Hu; Santhi Devasundaram; Dimitris Stellas; Bhabadeb Chowdhury; Jenifer Bear; Robert Burns; Duncan Donohue; Laurent Pessaint; Hanne Andersen; Mark G Lewis; Evangelos Terpos; Meletios Athanasios Dimopoulos; Alexander Wlodawer; James I Mullins; David J Venzon; George N Pavlakis; Barbara K Felber Journal: PLoS Pathog Date: 2021-09-22 Impact factor: 6.823
Authors: Ignacio Ordiz; José A Vega; Raquel Martín-Sanz; Olivia García-Suárez; Miguel E Del Valle; Jorge Feito Journal: Pharmaceutics Date: 2021-11-26 Impact factor: 6.321